Search Results - "KRARUP, T"

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity by Knop, F. K., Aaboe, K., Vilsbøll, T., Vølund, A., Holst, J. J., Krarup, T., Madsbad, S.

“…Aims: People with type 2 diabetes mellitus (T2DM) are characterized by reduced incretin effect and inappropriate glucagon levels. We evaluated α and β‐cell…”
Get full text

A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes by Moltke, Ida, Grarup, Niels, Jørgensen, Marit E., Bjerregaard, Peter, Treebak, Jonas T., Fumagalli, Matteo, Korneliussen, Thorfinn S., Andersen, Marianne A., Nielsen, Thomas S., Krarup, Nikolaj T., Gjesing, Anette P., Zierath, Juleen R., Linneberg, Allan, Wu, Xueli, Sun, Guangqing, Jin, Xin, Al-Aama, Jumana, Wang, Jun, Borch-Johnsen, Knut, Pedersen, Oluf, Nielsen, Rasmus, Albrechtsen, Anders, Hansen, Torben

“…An association mapping study of type-2-diabetes-related quantitative traits in the Greenlandic population identified a common variant in TBC1D4 that increases…”
Get full text

Whole-Exome Sequencing of 2,000 Danish Individuals and the Role of Rare Coding Variants in Type 2 Diabetes by Lohmueller, Kirk E., Sparsø, Thomas, Li, Qibin, Andersson, Ehm, Korneliussen, Thorfinn, Albrechtsen, Anders, Banasik, Karina, Grarup, Niels, Hallgrimsdottir, Ingileif, Kiil, Kristoffer, Kilpeläinen, Tuomas O., Krarup, Nikolaj T., Pers, Tune H., Sanchez, Gaston, Hu, Youna, DeGiorgio, Michael, Jørgensen, Torben, Sandbæk, Annelli, Lauritzen, Torsten, Brunak, Søren, Kristiansen, Karsten, Li, Yingrui, Hansen, Torben, Wang, Jun, Nielsen, Rasmus, Pedersen, Oluf

“…It has been hypothesized that, in aggregate, rare variants in coding regions of genes explain a substantial fraction of the heritability of common diseases. We…”
Get full text

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients by VILSBØLL, T, KRARUP, T, MADSBAD, S, HOLST, J. J

“…Glucagon-like-peptide-1 (GLP-1) is strongly insulinotropic in patients with Type II (non-insulin-dependent) diabetes mellitus, whereas glucose-dependent…”
Get full text

Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications by FRYSTYK, J, TAMOW, L, HANSEN, T. Krarup, PARVING, H.-H, FLYVBJERG, A

“…Low serum adiponectin (ADPN) has been associated with increased risk of cardiovascular disease (CVD) and retinopathy in patients with type 2 diabetes mellitus…”
Get full text

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes by Højberg, P. V, Vilsbøll, T, Rabøl, R, Knop, F. K, Bache, M, Krarup, T, Holst, J. J, Madsbad, S

“…Objective The incretin effect is attenuated in patients with type 2 diabetes mellitus, partly as a result of impaired beta cell responsiveness to…”
Get full text

Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects by Vilsbøll, T., Agersø, H., Krarup, T., Holst, J. J.

“…We have previously shown that type 2 diabetic patients have decreased plasma concentrations of glucagon-like peptide 1 (GLP-1) compared with healthy subjects…”
Get full text

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors by Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., Krarup, T.

“…Aims To examine whether 12 weeks of treatment with a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, sitagliptin, influences the insulin secretion induced by…”
Get full text

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial by Nordklint, A. K., Almdal, T. P., Vestergaard, P., Lundby-Christensen, L., Boesgaard, T. W., Breum, L., Gade-Rasmussen, B., Sneppen, S. B., Gluud, C., Hemmingsen, B., Jensen, T., Krarup, T., Madsbad, S., Mathiesen, E. R., Perrild, H., Tarnow, L., Thorsteinsson, B., Vestergaard, H., Lund, S. S., Eiken, P.

“…Summary Some antihyperglycemic medications have been found to affect bone metabolism. We assessed the long-term effects of metformin compared with placebo on…”
Get full text

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes by Courrèges, J.-P., Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáñová, I., Madsbad, S.

Get full text

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus by Knop, F. K, Vilsbøll, T, Madsbad, S, Holst, J. J, Krarup, T

“…Aims/hypothesis We investigated glucagon responses during OGTT and isoglycaemic i.v. glucose infusion, respectively, to further elucidate the mechanisms behind…”
Get full text

Association Testing of Novel Type 2 Diabetes Risk Alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 Loci With Insulin Release, Insulin Sensitivity, and Obesity in a Population-Based Sample of 4,516 Glucose-Tolerant Middle-Aged Danes by GRARUP, Niels, ANDERSEN, Gitte, KRARUP, Nikolaj T, ALBRECHTSEN, Anders, SCHMITZ, Ole, JØRGENSEN, Torben, BORCH-JOHNSEN, Knut, HANSEN, Torben, PEDERSEN, Oluf

“…Association Testing of Novel Type 2 Diabetes Risk Alleles in the JAZF1 , CDC123 / CAMK1D , TSPAN8 , THADA , ADAMTS9 , and NOTCH2 Loci With Insulin Release,…”
Get full text

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus by Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H.-H., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le-Thi, T., Madsbad, S.

“…Aims  To assess the effect of liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue on pancreatic B‐cell function. Methods  Patients with Type 2…”
Get full text

Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus by Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., Holst, J. J.

“…Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones secreted in response to meal ingestion, thereby…”
Get full text

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus by Aaboe, K, Knop, F.K, Vilsbøll, T, Deacon, C.F, Holst, J.J, Madsbad, S, Krarup, T

“…Aim: To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal…”
Get full text

The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype by Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., Holst, J. J.

“…The effect of the insulinotropic incretin hormone, glucagon-like peptide-1 (GLP-1), is preserved in typical middle-aged, obese, insulin-resistant type 2…”
Get full text

Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes by Jensen, D. H., Aaboe, K., Henriksen, J. E., Vølund, A., Holst, J. J., Madsbad, S., Krarup, T.

“…Aims/hypothesis The aim of this study was to evaluate the separate impact of insulin resistance and impaired glucose tolerance (IGT) on the incretin effect…”
Get full text

Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial by Hansen, Christian Stevns, Lundby-Christiansen, Louise, Tarnow, Lise, Gluud, Christian, Hedetoft, Christoffer, Thorsteinsson, Birger, Hemmingsen, Bianca, Wiinberg, Niels, Sneppen, Simone B, Lund, Søren S, Krarup, Thure, Madsbad, Sten, Almdal, Thomas, Carstensen, Bendix, Jørgensen, Marit E

“…Metformin has been shown to have both neuroprotective and neurodegenerative effects. The aim of this study was to investigate the effect of metformin in…”
Get full text

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes by Højberg, P. V, Zander, M, Vilsbøll, T, Knop, F. K, Krarup, T, Vølund, A, Holst, J. J, Madsbad, S

“…Aims/hypothesis The ability of glucagon-like peptide-1 (GLP-1) to enhance beta cell responsiveness to i.v. glucose is impaired in patients with type 2 diabetes…”
Get full text

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes by Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., Madsbad, S.

“…Objective   The aim of the present study was to investigate whether 4 weeks of near‐normalization of blood glucose (BG) improves incretin hormone secretion and…”
Get full text